Wire · opportunities
Cleo Diagnostics to Commence Analytical Validation of Pre-Surgical Ovarian Cancer Blood Test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 September 2026 · Fusion42 review
Cleo Diagnostics is commencing analytical validation of its pre-surgical ovarian cancer blood test with a batch of commercial test kits, advancing toward FDA submission and commercialization. This includes a strengthened assay with eight biomarkers to ensure reproducibility and robustness, followed by clinical validation through a pivotal US trial.
This Wire brief sits within Fusion42's coverage of Diagnostics.
◆ ◆ The Wire takeaway
Diagnostic founders focused on cancer testing can now plan for regulatory advances as Cleo moves into FDA submission with validated commercial kits. This opens a path for smaller players to accelerate clinical validation and regulatory filing for novel biomarker tests.
◆ Coverage
1 source · 3 Sep 2026
◆ Related on Wire
◆ Topics